Patents by Inventor Federico M. Gomez

Federico M. Gomez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140194632
    Abstract: Natural and synthetic compounds of Formulae Ia-Ie having a lactone structure, in particular Securolide, have been determined to be effective anti-tumor compounds which target the hrad9 gene and/or protein encoded thereby or complex containing the protein and/or the p53 gene and/or protein. Securolide is cytoselective for mutants of hRad9 based on studies conducted in Rad9 mutant yeast strains. Securolide appears to interact with mutant hRad9 in cancer cells to produce DNA lesions which result in apoptosis. Studies have demonstrated that Securolide is useful for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer, and to alleviate pain associated with the cancer.
    Type: Application
    Filed: August 5, 2013
    Publication date: July 10, 2014
    Applicant: Magnachem International Laboratories, Inc.
    Inventors: Federico M. Gomez, C. Federico Gomez Garcia-Godoy, David Terrero
  • Patent number: 8546444
    Abstract: Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly.
    Type: Grant
    Filed: May 28, 2012
    Date of Patent: October 1, 2013
    Assignee: Magnachem International Laboratories, Inc.
    Inventors: Federico M. Gomez, C. Federico Gomez Garcia-Godoy
  • Patent number: 8501431
    Abstract: Natural and synthetic compounds of Formulae Ia-Ie having a lactone structure, in particular Securolide, have been determined to be effective anti-tumor compounds which target the hrad9 gene and/or protein encoded thereby or complex containing the protein and/or the p53 gene and/or protein. Securolide is cytoselective for mutants of hRad9 based on studies conducted in Rad9 mutant yeast strains. Securolide appears to interact with mutant hRad9 in cancer cells to produce DNA lesions which result in apoptosis. Studies have demonstrated that Securolide is useful for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer, and to alleviate pain associated with the cancer.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: August 6, 2013
    Assignee: Magnachem International Laboratories, Inc.
    Inventors: David Terrero, Federico M. Gomez, C. Federico Gomez Garcia-Godoy
  • Publication number: 20120231050
    Abstract: Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly.
    Type: Application
    Filed: May 28, 2012
    Publication date: September 13, 2012
    Inventors: Federico M. Gomez, C. Federico Garcia Gomez-Godoy
  • Patent number: 8188145
    Abstract: Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: May 29, 2012
    Assignee: Magnachem International Laboratories, Inc.
    Inventors: Federico M. Gomez, C. Federico Gomez Garcia-Godoy
  • Publication number: 20100137618
    Abstract: Natural and synthetic compounds of Formulae Ia-Ie having a lactone structure, in particular Securolide, have been determined to be effective anti-tumor compounds which target the hrad9 gene and/or protein encoded thereby or complex containing the protein and/or the p53 gene and/or protein. Securolide is cytoselective for mutants of hRad9 based on studies conducted in Rad9 mutant yeast strains. Securolide appears to interact with mutant hRad9 in cancer cells to produce DNA lesions which result in apoptosis. Studies have demonstrated that Securolide is useful for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer, and to alleviate pain associated with the cancer.
    Type: Application
    Filed: October 26, 2009
    Publication date: June 3, 2010
    Inventors: Federico M. Gomez, C. Federico Gomez Garcia-Godoy, David Terrero